Your State Is Considering Passage Of A Statute That Exempts

Your State Is Considering Passage Of A Statute That Exempts Possession

Your state is considering passage of a statute that exempts possession and use of marijuana from prosecution if it is used for medical purposes. One of the cases that has been used to support the statute is that of Regina S., a 65-year-old woman, who has a son who has been undergoing treatment for cancer. The chemotherapy treatment made her son nauseous and he was in pain. Prescribed medication was not working, and Regina read that marijuana might be of help to her son. Regina is a gardener and decided to start growing marijuana in her back yard in order to give it to her son. The marijuana helped his nausea and discomfort.

The following memo explores the history of marijuana prohibition in the United States, how controlled substances are categorized into Schedules I-V, and specifically where marijuana is classified along with the reasons for its scheduling. It also discusses the effects of marijuana on brain and behavior, its potential for addiction, and scientific evidence for its medicinal benefits. Additionally, the memo provides a perspective on support for medical marijuana legislation and recreational use legalization, supported by relevant research.

Paper For Above instruction

Introduction

The legality and regulation of marijuana in the United States have evolved significantly over the past century. Historically, marijuana was widely used both medicinally and recreationally, but its status changed dramatically with criminalization efforts, leading to complex legal frameworks at both federal and state levels. As states consider legislation to legalize or decriminalize marijuana, understanding its historical context, biological effects, and medical potential is essential for informed policymaking.

History of Marijuana Prohibition in the U.S.

Marijuana prohibition in the United States began in the early 20th century, with the first federal regulations emerging in the 1930s. The Marihuana Tax Act of 1937 marked the start of nationwide criminalization, driven partly by racial and political motives. This act effectively banned possession and sale of marijuana, with penalties spanning fines and imprisonment. Throughout the 20th century, anti-marijuana rhetoric intensified, exemplified by the 1970 Controlled Substances Act (CSA), which categorized drugs into schedules and set the legal foundation for drug enforcement policies. Marijuana was classified as a Schedule I substance, indicating high potential for abuse and no accepted medical use, fostering strict penalties and research restrictions for decades.

Classification of Controlled Substances: Schedules I-V

The U.S. federal government categorizes controlled substances into five schedules (I-V) based on their medicinal value, potential for abuse, and safety profiles. Schedule I drugs are considered the most dangerous with no accepted medical use and high abuse potential, such as heroin, LSD, and, until recently, marijuana. Schedule II drugs have recognized medical uses but carry a high risk of dependence, including opioids like heroin, methamphetamine, and cocaine. Schedules III, IV, and V include drugs with decreasing abuse potential and increasing accepted therapeutic uses, such as certain sedatives, antidepressants, and cough preparations with limited quantities of controlled substances.

Marijuana’s Schedule Classification and Rationale

Marijuana remains classified as a Schedule I substance under federal law, despite evolving state laws permitting medical and recreational use. The classification hinges on federal agencies’ assessment that marijuana has high potential for abuse and no recognized medical use. However, this classification is controversial because numerous scientific studies have demonstrated its medicinal benefits, challenging the criteria used for scheduling. Critics argue that marijuana’s Schedule I status impedes research and clouded legal interpretation, especially as many states recognize its potential for treating conditions like chronic pain, nausea, and spasticity.

Effects of Marijuana on the Brain and Behavior

Marijuana’s primary psychoactive component, delta-9-tetrahydrocannabinol (THC), interacts with cannabinoid receptors in the brain, particularly in the hippocampus, basal ganglia, and cerebral cortex. This interaction influences memory, coordination, mood, and perception. Short-term effects include euphoria, relaxation, altered time perception, impaired memory, and decreased motor coordination. Long-term use has been associated with cognitive impairments, especially when initiated during adolescence, and can alter brain development. Behavioral effects can include impaired decision-making, motivation, and emotional regulation.

Addiction Potential of Marijuana

Research indicates that marijuana can be addictive, with approximately 9% of users developing cannabis use disorder, similar to other substances like alcohol. The risk increases among adolescent users and those who use frequently. Dependence is characterized by cravings, withdrawal symptoms (irritability, sleep disturbances, decreased appetite), and continued use despite adverse consequences. Neurobiological studies suggest that THC affects the brain’s reward system, reinforcing repeated use. Nonetheless, compared to substances like opioids or stimulants, marijuana’s addiction potential is considered relatively moderate.

Medicinal Benefits of Marijuana

Scientific studies have provided evidence supporting the medicinal benefits of marijuana. Research indicates its efficacy in alleviating chronic pain, reducing nausea and vomiting associated with chemotherapy, and suppressing muscle spasms in multiple sclerosis patients. For example, a review published in JAMA Internal Medicine found that cannabinoids can be effective for pain management, particularly in cancer-related pain and neuropathy. Additionally, animal studies and clinical trials support its role in glaucoma treatment, appetite stimulation, and symptom relief in terminal illnesses. The advent of cannabidiol (CBD), a non-intoxicating compound in marijuana, has further expanded its therapeutic potential for epilepsy and anxiety disorders.

Support for Medical Marijuana Legislation and Recreational Use

Many researchers and health professionals advocate for the legal recognition of medical marijuana, citing the substantial body of evidence demonstrating its safety and benefits when used appropriately. Legalization can improve patient access to alternative pain therapies and reduce reliance on opioids, thereby helping curb the opioid epidemic. Conversely, support for recreational legalization is often driven by considerations of personal freedom, economic benefits from taxation, and reduced criminal justice costs associated with marijuana enforcement. Studies from states where recreational use has been legalized, such as Colorado and California, suggest decreases in arrests related to marijuana and economic growth via taxing sales, while concerns remain over potential increases in adolescent use and impaired driving rates.

Conclusion

The historical prohibition of marijuana and its current classification as a Schedule I drug stand in contrast to mounting scientific evidence of its medicinal benefits. While marijuana’s psychoactive effects and addiction potential warrant cautious regulation, its therapeutic value—supported by extensive research—advocates for re-evaluating its legal status. Policymakers should consider scientific findings and societal impacts when proposing legislation that balances medical benefits, public safety, and personal liberties. The ongoing evolution of marijuana laws reflects a complex interplay between science, law, and social attitudes, warranting informed and evidence-based approaches.

References

  • Bornheim, K. A. (2014). Marijuana: A scientific and clinical review. Pharmacology & Therapeutics, 138, 107–124.
  • Hall, W., & Weier, M. (2015). Assessing the public health impacts of legalizing recreational cannabis use in the USA. Clinical Pharmacology & Therapeutics, 97(6), 607–615.
  • Kalant, H. (2001). The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs. Addiction, 96(8), 1189–1206.
  • National Academies of Sciences, Engineering, and Medicine. (2017). The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies Press.
  • Pacula, R. L., & Kilmer, B. (2015). Marijuana law, taxation and regulation: The case of California. Annual Review of Law and Social Science, 11, 339–359.
  • Reiman, A., et al. (2017). Cannabis as a substitute for prescription drugs—a retrospective review of patient data. The Journal of Psychoactive Drugs, 49(5), 377–385.
  • Russo, E. B. (2016). History of cannabis and its preparations in saga, science, and sobriquet. Chemistry & Biodiversity, 13(9), 1–22.
  • Schröder, J., & Zaiss, M. (2017). Medical cannabis in Germany—Progress and challenges. Journal of Cannabis Research, 1(1), 1–8.
  • Volkow, N. D., et al. (2014). Adverse health effects of marijuana use. New England Journal of Medicine, 370(23), 2219–2227.
  • Zhou, Y., et al. (2016). The pharmacology and toxicology of cannabinoids. CNS & Neurological Disorders - Drug Targets, 15(3), 241–255.

Related Assignments